Your AI-Trained Oncology Knowledge Connection!


Commentary

Video

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Fact checked by:

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

“At week 24, there [was a] 65.9% improvement in SVR35 at week 24 in the [pelabresib plus ruxolitinib] arm vs a 35% [improvement] in the [ruxolitinib alone] arm. Clearly, the combination has shown a significant improvement in SVR35.”

Ashwin Kishtagari, MD, assistant professor, medicine, hematology oncology, Vanderbilt University Medical Center, discusses updated findings from the phase 3 MANIFEST-2 trial (NCT04603495), which evaluated the addition of pelabresib (CPI-0610) to ruxolitinib (Jakafi) in JAK inhibitor–naive patients with myelofibrosis. The study assessed improvements in spleen volume, total symptom score (TSS), anemia, and bone marrow fibrosis at 24 weeks.

The study met its primary end point, demonstrating that a significantly higher proportion of patients who received the combination regimen (n = 214) achieved a 35% or greater reduction in spleen volume (SVR35) at week 24 compared with those who received ruxolitinib alone (n = 216), at 65.9% vs 35.2%, respectively (difference, 30.4%; 95% CI, 21.6%-39.3%; P < .001). The mean percentage change in spleen volume from baseline was –50.6% (95% CI, –53.2% to –48.0%) in the combination arm vs –30.6% (95% CI, –33.7% to –27.5%) in the monotherapy arm.

Secondary end points included improvement in TSS at week 24. Patients who received pelabresib plus ruxolitinib experienced a trend toward greater reduction in symptom burden compared with those who received ruxolitinib alone. Additionally, the combination therapy was associated with improvements in anemia and bone marrow fibrosis, suggesting its potential disease-modifying effects.

Kishtagari highlights that this trial included a broad population of patients with myelofibrosis, encompassing those with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. Unlike other trials that only enrolled intermediate-2 and high-risk patients, MANIFEST-2 also included patients with intermediate-1 risk disease.

Given the demonstrated improvements in SVR and symptom burden, Kishtagari notes that these findings support the potential role of BET inhibition in combination with JAK inhibition as a first-line treatment approach for patients with myelofibrosis.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Shilpa Gupta, MD, director of Genitourinary Medical Oncology at the Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program in the Department of Hematology and Medical Oncology, Cleveland Clinic; as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center
Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine
SHAH
Timothy S. Fenske, MD, MS
Sheela Rao, MBBS, MD, FRCP
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD